GLP-1 Agonists: A Promising Treatment for Non-Alcoholic Fatty Liver Disease

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

GLP-1 agonists show promise in treating non-alcoholic fatty liver disease by improving liver fat content, reducing inflammation, and enhancing metabolic health.

# GLP-1 Agonists for Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) has become a major public health concern worldwide, affecting approximately 25% of the global population. Its progression can lead to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma. Given the limited pharmacological options for NAFLD, glucagon-like peptide-1 (GLP-1) receptor agonists have garnered significant interest as a potential therapeutic option.

This article provides an overview of the role of GLP-1 agonists in managing NAFLD, their mechanisms of action, dosing protocols, and the current evidence supporting their use.

---

Understanding NAFLD and Its Pathophysiology

NAFLD is characterized by excessive fat accumulation (>5% hepatic steatosis) in the liver cells in individuals who consume little to no alcohol. The spectrum ranges from simple steatosis to NASH, the latter involving inflammation and hepatocellular injury.

Key risk factors include:

  • Obesity
  • Insulin resistance and type 2 diabetes mellitus (T2DM)
  • Dyslipidemia
  • Metabolic syndrome

    • Insulin resistance plays a central role by promoting increased lipolysis in adipose tissue and enhancing hepatic de novo lipogenesis, leading to fat deposition in the liver.

    ---

    What are GLP-1 Agonists?

    GLP-1 agonists are a class of injectable or oral antidiabetic medications that mimic the action of endogenous GLP-1, an incretin hormone released by the gut in response to food intake. They stimulate insulin secretion, inhibit glucagon release, slow gastric emptying, and promote satiety.

    Common examples include:

  • Liraglutide (Victoza)
  • Semaglutide (Ozempic, Rybelsus)
  • Dulaglutide (Trulicity)
  • Exenatide (Byetta, Bydureon)

    • These agents are primarily approved for type 2 diabetes and obesity but have shown promising results in liver fat reduction and improvement of histological features in NAFLD.

    ---

    Mechanisms by Which GLP-1 Agonists Benefit NAFLD

  • Improved Insulin Sensitivity: GLP-1 agonists reduce insulin resistance, which decreases hepatic lipogenesis and triglyceride accumulation.
  • Weight Loss: By reducing appetite and food intake, GLP-1 receptor agonists promote weight loss, a key factor in NAFLD improvement.
  • Anti-inflammatory Effects: These agents may directly reduce hepatic inflammation and oxidative stress.
  • Reduction in Liver Fat Content: Multiple studies have shown reductions in hepatic steatosis measured by imaging techniques such as MRI-PDFF (magnetic resonance imaging proton density fat fraction).

    • ---

    Evidence Supporting GLP-1 Agonists in NAFLD Treatment

    Liraglutide

  • LEAN Trial (2016): A randomized placebo-controlled trial evaluating liraglutide 1.8 mg daily in patients with biopsy-proven NASH.

    • - Outcomes: 39% of liraglutide-treated patients had resolution of steatohepatitis vs 9% in placebo.

    - Liraglutide significantly reduced liver enzymes and prevented fibrosis progression.

    Semaglutide

  • A 72-week phase 2 trial investigating semaglutide (0.1 mg, 0.2 mg, or 0.4 mg daily subcutaneous) in NASH patients.

    • - Outcomes: Dose-dependent NASH resolution with the highest dose achieving up to 59% resolution versus 17% in placebo.

    - However, fibrosis improvement was not statistically significant.

  • Oral semaglutide is also being studied but data are preliminary.

    • Other GLP-1 Agonists

  • Exenatide and dulaglutide have shown beneficial effects on liver enzymes and hepatic steatosis in smaller or observational studies.

    • ---

    Practical Protocol for Using GLP-1 Agonists in NAFLD

    Patient Selection

  • Adults with biopsy-proven NASH or significant hepatic steatosis with metabolic risk factors (T2DM, obesity).
  • Patients should have no contraindications to GLP-1 agonists (e.g., history of medullary thyroid carcinoma, pancreatitis).
  • Optimization of other risk factors (weight loss, glycemic control) remains essential.

    • Dosing Guidelines

    | GLP-1 Agonist | Starting Dose | Maintenance Dose | Administration |

    |---------------|--------------|------------------|-------------------|

    | Liraglutide | 0.6 mg daily | Increase by 0.6 mg weekly to 1.8 mg daily | Subcutaneous injection |

    | Semaglutide | 0.25 mg weekly | Titrated to 0.5-1 mg weekly (up to 2.4 mg weekly in some studies) | Subcutaneous injection |

    | Dulaglutide | 0.75 mg weekly | Increase to 1.5 mg weekly as needed | Subcutaneous injection |

    | Exenatide | 5 mcg twice daily | Increase to 10 mcg twice daily | Subcutaneous injection |

    Note: Doses for NAFLD treatment reflect those used in diabetes/obesity trials, as there is no FDA-approved indication specifically for NAFLD.

    Monitoring and Follow-Up

  • Baseline and periodic liver function tests (ALT, AST).
  • Imaging (ultrasound, controlled attenuation parameter by FibroScan, or MRI-PDFF) can quantify liver fat changes.
  • Monitor for adverse effects such as nausea, vomiting, or hypoglycemia.
  • Assess for sustained weight loss and glycemic control improvements.

    • ---

    Safety and Adverse Effects

    Common side effects of GLP-1 agonists include:

  • Gastrointestinal upset (nausea, diarrhea)
  • Potential risk of pancreatitis (rare)
  • Injection site reactions
  • Possible increase in heart rate

    • Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 agonists due to theoretical cancer risk.

    ---

    Conclusion

    GLP-1 receptor agonists represent a promising treatment avenue for NAFLD, especially in patients with comorbid obesity or type 2 diabetes. Their benefits extend beyond glycemic control, targeting the underlying metabolic dysfunction driving fatty liver accumulation and inflammation. Clinical trials, particularly with liraglutide and semaglutide, have demonstrated improvements in liver histology, steatosis, and inflammation.

    While further research is needed to establish long-term benefits and to gain official regulatory approval specifically for NAFLD, current evidence supports considering GLP-1 agonists in selected patients. It is crucial for patients to consult their healthcare provider before starting therapy to ensure individualized treatment and monitoring.

    ---

    References

  • Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690.
  • Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
  • Mantovani A, Rigolon R, Bonapace S, et al. GLP-1 receptor agonists and insulin resistance in NAFLD: molecular mechanisms and therapeutic opportunities. Front Endocrinol (Lausanne). 2022;13:904668.

    • ---

    This content is for informational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider for personalized recommendations.